Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

NCT06790706 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT06790706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06790706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 1, 2025
Completion date
June 30, 2031
Enrollment
27 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid carcinomas, carcinoid tumor, gastroenteropancreatic neuroendocrine tumor, gestational trophoblastic tumor, peritoneal mesothelioma, thymic carcinoma